Affimed (NASDAQ:AFMD) Short Interest Update

Affimed (NASDAQ:AFMD) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 846,900 shares, a growth of 38.5% from the November 30th total of 611,400 shares. Based on an average daily trading volume, of 253,700 shares, the short-interest ratio is presently 3.3 days. Approximately 6.5% of the company’s shares are short sold.

Analyst Ratings Changes

Several research firms have issued reports on AFMD. Wells Fargo & Company lowered their price objective on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th. Stifel Nicolaus reduced their price objective on Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Affimed in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Institutional Trading of Affimed

Several hedge funds and other institutional investors have recently bought and sold shares of AFMD. Choreo LLC bought a new position in shares of Affimed in the 2nd quarter worth $54,000. Point72 Asset Management L.P. grew its stake in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the last quarter. Intellectus Partners LLC raised its holdings in Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 10,250 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Affimed during the third quarter valued at about $44,000. Finally, FMR LLC boosted its holdings in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares in the last quarter. Institutional investors own 30.82% of the company’s stock.

Affimed Stock Up 1.6 %

NASDAQ AFMD opened at $1.29 on Friday. The firm’s 50 day moving average price is $2.76 and its 200-day moving average price is $3.91. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 52-week low of $1.14 and a 52-week high of $8.95.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.